In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amanda Micklus

Principal Analyst, Datamonitor Healthcare

Connecticut, US
Amanda has been tracking corporate strategy and business development activities in the biopharma and medtech industries for more than 10 years. She is a principal analyst with Informa’s Datamonitor Healthcare where she researches and analyzes trends in corporate strategy and dealmaking, and compiles reports for clients. Amanda also writes trends pieces for Informa’s IN VIVO and START-UP publications, and contributes to Informa’s Strategic Transactions deals database, researching and writing analyses on individual biopharma and medtech transactions. Before joining Informa, Amanda spent five years at Purdue Pharma, working as a market research analyst and information searcher. She has a Bachelor of Science degree in Chemistry-Business from the University of Scranton, and a Master of Science in Library & Information Science from Long Island University.
Set Alert for Articles By Amanda Micklus

Latest From Amanda Micklus

Deals In Depth: January 2018

In a $1.2 billion deal, Takeda and Denali are jointly developing and commercializing Alzheimer's antibodies. Celgene did two big oncology bolt-on acquisitions, buying Juno and Impact. Chinese company BeiGene completed a $758 million follow-on public offering.
Deals Market Intelligence

Deals Shaping The Medical Industry, March 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2018.  
Deals BioPharmaceutical

Device/Diagnostics Quarterly Deal-Making Statistics, Q4 2017

Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.

Deals Market Intelligence

Biopharma Quarterly Deal-making Statistics, Q4 2017

Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.

Deals Market Intelligence

Deals In Depth: December 2017

In a billion-dollar alliance, Roivant Sciences got exclusive rights to HanAll's neonatal Fc receptor-targeting antibody for autoimmune diseases. CVS is hoping to improve health care delivery and costs with the $77 billion acquisition of insurer Aetna. Financing in both the biopharma and devices industries was down from last month.

Deals Market Intelligence

Growing Pipelines, Promising Candidates Bring Gene Therapy To The Next Level

Advances in gene therapy have created a dynamic pipeline. A recent Datamonitor Healthcare report examines various trends in that pipeline, including vector types used, in vivo versus ex vivo approaches, and therapy areas being targeted.

Regenerative Medicine Market Intelligence
See All